Table 2.

Fifteen uncontrolled clinical studies with nitroxoline in 947 adult patients of both genders

First author	Year	Pat (n)	Indication (T/P)	Dosage	Duration	Success rate	Adverse events
Kuss [43]	1962	72	T: acute cUTI & uUTI	400 mg/d	20–45 days	78%	1.3% gastrointestinal
Moreau [44]	1962	20	T: acute cUTI	400–500 mg/d	8–10 (−45) days	90%	5% gastrointestinal
v. Rütte [45]	1969	200	P: chronic rUTI	300–500 mg/d	2–3 months	80%	0%
				shortly 800 mg/d	1 day
Uhlir [46]	1972	20	T: acute UTI (7), chronic PN (13)	300 mg/d	14 days	100%	0%
Allal [47]	1973	264	T: UTI during pregnancy	300 mg/d	6 days	> 75%	No data
Bittard [48]	1974	50	P: post-op. catheter	7.5–10 mg/kg/d	6 weeks	92%	Few gastrointestinal
Schlesinger [49]	1975	65	T: chronic PN (62), chronic prostatitis (3)	300–500 mg/d	10 days	80% clinical	0%
Aubert [50]	1976	28	T: post-op. catheter, after endoscopy	200–300 mg/d	10–15 days	72%	0%
Dufour [51]	1979	15	T: acute prostatitis	900–1600 mg/d	3–5 days	81%	No data
Lenzner [52]	1983	60	T: fungal UTI	750 mg/d	10–20 days	80%	3.3% itching; few cases with nausea and vomiting
Schülke [53]	1984	50	T: postop., acute UTI after removal of urethral catheter for 3–10 days	750 mg/d	3 days	78%	0%
Sachse [54]	1984	44	P: chronic rUTI	750 mg/d	4 months	77% free of rUTI; rUTI rate decreased from 0.33 to 0.11/month	9% gastrointestinal 2.2% exanthema
Demontrond [55]	1986	15	T: candiduria in hospitalised patients	600 mg/d	10–30 days	87%	0%
Frobert [56]	1987	36	T: acute, uUTI in hospitalised patients	600 mg/d	10 days	93% bacteriological	5.5% gastrointestinal
						87% clinical	2.7% nausea
							2.7% dizziness
Cancet [27]	1987	8	T: urogenital fungal infections	600 mg/d	15 days	100%	no data

T-therapy; P-prophylaxis; UTI-urinary tract infection; uUTI-uncomplicated UTI; cUTI-complicated UTI; PN-pyelonephritis.